C9150 — Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
C9150 is a HCPCS Level II code for xenon xe-129 hyperpolarized gas, diagnostic, per study dose. It belongs to the Outpatient Prospective Payment System section. It was terminated on September 30, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated C9150 on September 30, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9150
- Long descriptor
- Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
- Short descriptor
- Xe129 xenon, diagnostic
- Added
- July 1, 2023
- Terminated
- September 30, 2024
- BETOS
- I1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9150
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9150 is not quite right, the correct code is very often within a few positions of it.
- C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgterminated
- C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
- C9144Injection, bupivacaine (posimir), 1 mg
- C9145Injection, aprepitant, (aponvie), 1 mgterminated
- C9146Injection, mirvetuximab soravtansine-gynx, 1 mgterminated
- C9147Injection, tremelimumab-actl, 1 mgterminated
- C9148Injection, teclistamab-cqyv, 0.5 mgterminated
- C9149Injection, teplizumab-mzwv, 5 mcgterminated
- C9151Injection, pegcetacoplan, 1 mgterminated
- C9152Injection, aripiprazole, (abilify asimtufii), 1 mgterminated
- C9153Injection, amisulpride, 1 mgterminated
- C9154Injection, buprenorphine extended-release (brixadi), 1 mgterminated
- C9155Injection, epcoritamab-bysp, 0.16 mgterminated
- C9156Flotufolastat f 18, diagnostic, 1 millicurieterminated
- C9157Injection, tofersen, 1 mgterminated
- C9158Injection, risperidone, (uzedy), 1 mgterminated
Questions about C9150
What is HCPCS code C9150?
C9150 is a HCPCS Level II code for xenon xe-129 hyperpolarized gas, diagnostic, per study dose. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9150?
The CMS HCPCS file marks C9150 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9150 still valid?
No. C9150 was terminated on September 30, 2024 and should not be used on new claims.